Single dose testosterone increases total cholesterol levels and induces the expression of HMG CoA Reductase by Gårevik, Nina et al.
RESEARCH Open Access
Single dose testosterone increases total
cholesterol levels and induces the expression of
HMG CoA Reductase
Nina Gårevik, Cristine Skogastierna, Anders Rane and Lena Ekström
*
Abstract
Background: Cholesterol is mainly synthesised in liver and the rate-limiting step is the reduction of 3-hydroxy-
3methylglutaryl coenzyme A (HMG-CoA) to mevalonate, a reaction catalysed by HMG-CoA reductase (HMGCR).
There is a comprehensive body of evidence documenting that anabolic-androgenic steroids are associated with
deleterious alterations of lipid profile. In this study we investigated whether a single dose of testosterone
enanthate affects the cholesterol biosynthesis and the expression of HMGCR.
Methods: 39 healthy male volunteers were given 500 mg testosterone enanthate as single intramuscular dose of
Testoviron
®–Depot. The total cholesterol levels prior to and two days after testosterone administration were
analysed. Protein expression of HMGCR in whole blood was investigated by Western blotting. In order to study
whether testosterone regulates the mRNA expression of HMGCR, in vitro studies were performed in a human liver
cell-line (HepG2).
Results: The total cholesterol level was significantly increased 15% two days after the testosterone injection (p = 0.007).
This is the first time a perturbation in the lipoprotein profile is observed after only a single dose of testosterone.
Moreover, the HMGCR mRNA and protein expression was induced by testosterone in vitro and in vivo, respectively.
Conclusion: Here we provide a molecular explanation how anabolic androgenic steroids may impact on the
cholesterol homeostasis, i.e. via an increase of the HMGCR expression. Increasing knowledge and understanding of
AAS induced side-effects is important in order to find measures for treatment and care of these abusers.
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Background
Anabolic androgenic steroids (AAS) including testoster-
one, other endogenous androgenic hormones and syn-
thetic substances structurally related to these compounds
are the most frequently detected doping agents in the
society and sports. The abuse of these agents for cos-
metic purposes among non-competitive recreational
body-builders and non-athletes is a considerable health
concern. According to studies in Western societies the
prevalence of abuse of anabolic androgenic steroids
among high school and college students ranges from 1 to
5% [1-3].
There is a comprehensive body of evidence document-
ing that AAS induce various deleterious alterations of the
lipoprotein profile. The most prominent changes include
elevations of low density lipoprotein (LDL) and decreases
of high density lipoprotein (HDL) [4-7]. The long-term
consequences of these alterations are still unknown but it
is possible that the perturbation of the lipid profile may be
associated with an increase in risk of coronary artery
disease.
Cholesterol is mainly synthesised in the liver and the
rate-limiting step is the reduction of 3-hydroxy-3methyl-
glutaryl coenzyme A (HMG-CoA) to mevalonate, a reac-
tion catalysed by HMG-CoA reductase (HMGCR).
Normally in mammalian cells the transcription of
HMGCR is suppressed by cholesterol derived from the
internalization and degradation of LDL via the LDL
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tins lead to induction of the expression of LDL receptors
in the liver, which in turn increases the catabolism of
plasma LDL and lowers the concentration of cholesterol
in plasma. It is conceived that statins have a preventive
effect on cardiovascular disease to a great extent by these
mechanisms in several populations [8].
In this study we investigated whether a single dose of
testosterone enanthate affects the cholesterol profile and
the expression of HMGCR in healthy volunteers. The
lipoprotein profile was analysed prior to, and two and fif-
teen days after administration of 500 mg testosterone
enanthate. The protein expression of HMGCR in whole
blood was determined by Western blotting. Moreover,
human liver cells (HepG2) were exposed to supra-physio-
logical concentrations of testosterone enathate and the
mRNA HMGCR level was quantified by real time
analysis.
Methods
Subjects and design
Study subjects included 39 healthy volunteers originating
from the study population described in detail elsewhere
[9]. All participants were males at age 18-50 years, and
gave informed consent consistent with the approval of the
Ethics Review Board. The participants were given 500 mg
testosterone enanthate as a single intramuscular dose of
Testoviron
®– Depot (kindly provided by Schering Nor-
diska AB, Solna) equivalent to 360 mg testosterone. Blood
and serum was collected prior to (day 0), 2 and 15 days
after testosterone administration. All samples were col-
lected between 07 and 11 am and were directly frozen at
-20°c.Averse drug reactions (ADRs) were monitored from
the time of screening until day 15 after administration of
testosterone. The study was conducted according to the
Helsinki declaration and the ICH Harmonised Tripartite
Guideline for Good Clinical Practice.
Western blotting
The level of the HMGCR enzyme in whole blood samples
was examined by Western blotring analysis. Frozen whole
blood samples were available from 24 subjects of the
39 individuals included in the study. The blood samples
were mixed 1:12 with 2 mM EDTA and complete protease
inhibitor cocktail (cat no 11 697 498 001 Roche) and
freeze-thawed three times. The hemolysates were sepa-
rated on 12% polyacrylamide gel, electrotransferred onto
Hybond-C extra membrane (GE healthcare), blocked over-
night in high salt base buffer (HSB) (50 mM Tris-HCl/500
mM NaCl, pH 7.5), 2% dried milk, 1% BSA and incubated
for two hours with 1:400 dilution of rabbit anti-HMGCR
antibody (Santa Cruz Biotechnology). Membranes were
washed in HSBT (HSB with 0.05% Tween) and incubated
for 1 hour with 1:2500 horseradish peroxidise-linked
mouse anti-rabbit immunoglobulin antibody (Promega,
WI, USA). Detection of the protein bands was carried out
using ECL Plus Western Blotting Detection System kit
(GE healthcare, Uppsala, Sweden) and quantified by densi-
tometry using BioRad Quantity One1 (version 4.1 soft-
ware). A standard curve with increasing concentration of
liver microsomes was included on each gel. The HMGCR
expression in whole blood was normalized against the
total protein level as was determined by Lowry [10].
Cell culture
HepG2 cells were cultured in MEM supplemented with
5% FCS, 1% penicillin/streptomycin, 1% L-glutamine and
maintained in humidified atmosphere at 37°C and 5%
CO2. Prior to testosterone treatment the HepG2 cells
were split and plated in 6-well plates and pre-incubated
for 3 days. Testosterone enanthate was diluted in ethanol
and added to the cells (1 μM) for 2-48 hours. The non-
treated controls were incubated with vehicle only. The
experiments were performed in four independent experi-
ments. For RNA extraction the cells were harvested with
Trizol (Invitrogen, UK) and kept at −80°C until analysis.
RNA extraction and cDNA
Total RNA extraction was performed using 0.5 ml Tri-
zol per well according to manufacturer´s instructions.
RNA (0.5 μg) was reverse transcribed into cDNA with
hexamer primer using first-strand cDNA synthesis kit
(Amersham Biosciences, NJ, USA) according to the
manufacturer´s protocol and diluted 10 X in sterile
water.
Real time PCR
The mRNA level of HMGCR in testosterone treated
HepG2 cells was determined by real-time PCR. Beta-
actin (PN 4326315E, Applied Biosystems, Foster City,
CA) was chosen as an endogenous housekeeping control
gene. Quantitative real-time PCR was performed using
the 7500 Fast system, Applied Biosystems. Reaction mix-
tures contained Taqman reaction mix (Applied Biosys-
tems), HMGCR Taqman Assay mix (Hs01103000_m1,
Applied Biosystems), 4 μl cDNA template in a total
volume of 20 μl. Thermal cycling conditions included
activation at 95°C (10 min) followed by 40 cycles each
of denaturation at 95°C (15 sec) and annealing/elonga-
tion at 60°C (1 min). Each reaction was performed in
triplicates and no-template controls were included in
each experiment. The untreated sample was employed
as a calibrator and the ΔΔ CT-formula was used as
described previously [11]. The gene expression was
quantified as the yield of the target gene relative to that
of Beta-actin gene.
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Serum total cholesterol, HDL, LDLD, alanine transami-
nase (ALAT) and aspartate transaminase (ASAT) were
determined by routine analyses at the division of clinical
chemistry, Karolinska University Hospital. Total testos-
terone levels in serum prior to and after testosterone
administration had been measured by GCMS in a pre-
vious study [12]
Data analysis
Statistical analyses were performed using GraphPad Prism
software 4.03 (GraphPad, San Diego, CA). The increase in
cholesterol levels after testosterone injection was com-
pared using ANOVA. The protein expression of HMGCR
prior to and after testosterone administration was com-
pared using Wilcoxon test whereas Mann-Whitney test
was used for comparison of HMGCR mRNA levels
between testosterone treated and non-treated HepG2 cells.
Results
Cholesterol levels
Total cholesterol level increased on day two (mean 4.87
mmol/L +/SD 0.25) compared to day 0 (mean 4.23
mmol/L +/− SD 0.27) (p = 0.007; ANOVA) (Figure 1).
On day 15 the total cholesterol level was back to base-
line (mean 4.23 +/− SD 0.14). There was no significant
difference in HDL, LDLD or VDL between day 0 and
day 2 (data not shown).
A correlation analysis demonstrates that the increase
in cholesterol levels was significantly correlated to the
total testosterone levels on day 2 (r
2 =0 . 1 4p=0 . 0 2 ;
Spearman´s rank correlation test). There were no altera-
tions in the liver function biomarkers ALAT and ASAT.
HMGCR expression in whole blood
The increase in cholesterol level prompted us to investi-
gate the expression of the main enzyme involved in the
cholesterol synthesis. The protein expression of HMGCR,
the rate limiting enzyme in the cholesterol synthesis, was
investigated by Western blotting in whole blood from the
subjects prior to, and two days after testosterone adminis-
tration. In 80% of the individuals the HMGCR expression
was increased 2 days after the administration of testoster-
one (Figure 2). In the whole group, there was a significant
increase in HMGCR expression on day two compared to
day 0 (p = 0.03; Mann Whitney test).
HMGCR mRNA expression in HepG2 cells
S i n c et e s t o s t e r o n ei n d u c e sH M G C Re x p r e s s i o nin vivo,
we investigated whether it would also affect the mRNA
expression of HMGCR in vitro. HepG2 cells were
exposed to testosterone enanthate (1 uM) for 2-48
hours. The gene expression of HMGCR was 1.8 fold
higher after 2 hours testosterone treatment (p < 0.001;
Figure 1 The change in total cholesterol levels on day 0 (prior to
testosterone administration), 2 and 15 days after testosterone
administration. The mean total cholesterol level was significantly
higher 2 days after testosterone administration as compared to on day
0 (p = 0.007; ANOVA). 15 days after testosterone administration the
total cholesterol level was back to baseline.
Figure 2 HMGCR protein levels in vivo.T h ef o l dc h a n g ei n
HMGCR protein expression in whole blood on day 2 was assessed
by Western blotting. The individual expression values on day 2 were
presented in relation to the level on day 0 which was set to one.
There was a significant increase in HMGCR level on day 2 (p = 0.03,
Mann Whitney test).
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decrease in HMGCR mRNA was observed after
24 hours (p = 0.047). After 48 hours the mRNA levels
were back to basal level.
Discussion
Even though accumulating evidence indicates that testos-
terone may have adverse effect on the lipoprotein profile
and cardiovascular health, this is, to the best of our knowl-
edge, the first time an increase in total cholesterol level
has been observed after only one single dose of testoster-
one. 15 days after the testosterone administration the cho-
lesterol levels in the volunteers was back to baseline levels.
Numerous reports on the effects of AAS on lipoproteins
in humans have been published in the last 25 years. To a
large extent the results of these studies present consistent
results, i.e. AAS cause a marked depression in serum HDL
and an elevation in LDL (as reviewed by [13] and [14]).
However, for the effect on total cholesterol levels the
results are conflicting. Some studies have found that
repeated supra-physiologic doses of AAS is associated
with an increase in total cholesterol levels [15,16], whereas
others have failed to find such an association [5,6]. The
reason for the discrepancy observed in the effect on total
cholesterol after AAS administration may be the different
study designs used, sampling time, type of AAS used,
administration route etc. However, most importantly,
these studies all concerned subjects with multiple doses or
chronic use of AAS.
The baseline serum testosterone concentration in our
study population was 5 ng/ml [12] which is the same as
has been seen in other study groups similar in respect of
age, gender, ethnicity [17]. Two days after testosterone
administration the serum testosterone level has increased
by 200% [12]. Here we show that circulatory concentration
of total testosterone was significantly associated with the
increase in cholesterol levels on day 2. No toxic effect on
liver function, as assessed by ALAT and ASAT, was found
indicating that the increase in total cholesterol observed is
directly associated with the administration of testosterone
and not an artificial effect of the injection, i.e. stress or
impact on the liver function.
The synthesis of cholesterol is dependent on the activ-
ity of HMGCR, and we therefore investigated if testoster-
one could affect the expression of this enzyme. Here we
show for the first time that a supra-physiological dose of
testosterone induces the expression of HMGCR in vivo
in healthy volunteers. These observations were supported
by the results from the experiments with HepG2 cells
exposed to 1 μM testosterone. This concentration is in
the range of the levels achieved after administration of
testosterone to the volunteers [12], and yielded a marked
induction of the transcription of the HMGCR gene.
Further support for this testosterone effect is provided
from experiments in castrated mice and male Sprague-
Dawley rats in which 14 days administration of AAS (tes-
tosterone and nandrolone) led to an up-regulation of
meibomian and adrenal genee x p r e s s i o no fH M G C R ,
respectively [18,19]. The mechanisms for the androgen
induced up-regulation of HMGCR transcription as well
as the physiological consequences have not been investi-
gated and needs to be further elucidated. High choles-
terol levels are known to exert a negative feedback on the
cholesterol synthesis on a transcriptional level [20,21].
This may explain the time dependent response observed
in our HepG2 experiments, i.e. the HMGCR mRNA
expression was normalized or even down-regulated
24 hours after testosterone treatment.
Other molecular mechanisms behind the unfavourable
effects of AAS on the lipoprotein profile have not been
well investigated. It is believed that AAS exert some of
their influence on the cholesterol profile by inducing the
HDL-catabolising enzyme hepatic triglyceride lipase
(HTGL) synthesis in the liver [5]. A 143-232% increase
of HTGL activity has been described during AAS abuse
[4]. Here we provide an additional molecular explana-
tion how AAS may impact on the cholesterol homeosta-
sis, i.e. via an increase of the HMGCR expression.
Further studies may provide yet other explanations
behind the lipid profile perturbation observed as a result
of AAS abuse.
A A Sa r et h em o s tc o m m o n l yu s e dd o p i n ga g e n t si n
athletes (http://www.wada-ama.org). However, the abuse
Figure 3 HMGCR mRNA levels in vitro. The effect of testosterone
enanthate on HMGCR mRNA levels in HepG2 cells was determined
at different time points. Cells were incubated with testosterone
enanthate or vehicle (C = control set as 1) and total RNA was
extracted, reverse transcribed and subjected to real-time PCR.
Measurements were performed in triplicates and data are presented
as means ± SD (N = 4). There was a significant increase in HMGCR
mRNA expression 2 hours after testosterone exposure (p < 0.001;
Mann Whitney test), whereas after 24 hours the levels was
significant lower (p = 0.047) as compared to the controls.
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spread to sport amateurs and non-athletes and is con-
sidered a serious concern in the society [2,22]. It is
therefore urgent to study and establish the awareness of
the adverse effects caused by AAS. Here we provide
scientific evidence that a supra-physiological dose of tes-
tosterone may have adverse effects on the cholesterol
metabolism. Our setting is, however, very different from
the situation for the illicit users that typically take AAS
in repeated courses known as “cycles”,e a c hl a s t i n gs e v -
eral weeks to several months. One might suspect that
the HMGCR expression will rapidly increase after each
dose, keeping the HMGCR protein expression and cho-
lesterol metabolism elevated continuously during the
“cycles”.
Some limitations of our study need to be addressed.
Using whole blood as surrogate model for HMGCR
expression may not reflect the expression profile in the
liver. Nevertheless, blood is a natural surrogate organ in
the absence of availability of liver biopsies. It is to be
noted that HMGCR and its main important transcription
factors, i.e. SREBP-2 are highly abundant in the blood
cells further supporting that whole blood may be used
for expression analysis. Another limitation is that we only
have the cholesterol profile in our study participants. The
inclusion of cholesterol activity biomarkers such as
lathosterol would further support that the administration
of supra-physiological doses of testosterone disturb the
cholesterol metabolism in vivo. Unfortunately our study
design did not permit further analysis of additional
biomarkers.
Conclusions
In conclusion, we have shown that already one single dose
of testosterone enanthate increases the serum total choles-
terol level. This immediate response to AAS is a cause for
concern and signals that the lipid metabolic perturbation
is a rapid response and warrants close follow-up of the
cardiovascular risk factors that may appear later in life in
abusers. There are many cases described in the literature
on such adverse events in heavy abusers of AAS. Our find-
ings demonstrate that such effects may occur also in sub-
jects with moderate, intermittent, or temporary abuse of
AAS. Therefore, given our findings, public efforts should
be centered on primary prevention.
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